Repatriation Medical Authority - Notice of Investigation - Diabetes Mellitus - focussed

Overview

The Repatriation Medical Authority (the Authority) under section 196G of the Veterans' Entitlements Act 1986 (the VEA) has issued a notice of an investigation into immune-checkpoint inhibitors and interferon as potential factors in diabetes mellitus. This investigation, announced in 2021, is conducted in the context of the Statements of Principles Instrument Nos. 48 and 49 of 2020 concerning diabetes mellitus. The Authority seeks submissions from eligible claimants under the VEA and the Military Rehabilitation and Compensation Act 2004, organisations representing various groups of service personnel and their dependants, and individuals with relevant expertise. The Authority's first meeting for this investigation is scheduled for 5 May 2021, and submissions must be received by 28 April 2021. This investigation aims to address potential gaps in understanding the impact of these medical treatments on veterans' health, particularly in relation to diabetes mellitus. The objective of this investigation is to fill a significant gap in the understanding and treatment of diabetes mellitus in veterans, which may have been influenced by medical treatments such as immune-checkpoint inhibitors and interferon. By inviting submissions from a broad range of stakeholders, including veterans, their representatives, and medical experts, the Authority aims to gather comprehensive insights and data to inform its findings and recommendations. This initiative underscores the commitment of the enacting body, the Parliament of Australia, to improve the health outcomes and entitlements of veterans, ensuring they receive appropriate care and recognition for conditions potentially linked to their service.

Scope and Application

The notice of investigation issued by the Repatriation Medical Authority (the Authority) under section 196G of the Veterans' Entitlements Act 1986 pertains to an inquiry into immune-checkpoint inhibitors and interferon as factors in diabetes mellitus. This investigation is being conducted in the context of Statements of Principles Instrument Nos. 48 and 49 of 2020 concerning diabetes mellitus. The Authority's notice extends an invitation to various stakeholders to submit written submissions, including individuals eligible for claims under the VEA or the Military Rehabilitation and Compensation Act 2004, organisations representing veterans and their dependants, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and individuals with relevant expertise. Submissions can be made electronically through the RMA website, via email, or by post, and must be received by the Authority no later than 28 April 2021. The investigation is a Commonwealth matter, reflecting the national scope of the legislative and administrative framework within which the Authority operates. The scope of the investigation is specifically tailored to the nexus between immune-checkpoint inhibitors, interferon, and diabetes mellitus as it affects veterans and eligible persons under the Act. While the Act and its related instruments provide a comprehensive framework, there are no explicit exclusions or thresholds outlined in the notice. The application of the investigation may be further detailed or extended through subordinate instruments, which could specify additional areas of inquiry or modify the scope as needed. However, the primary focus remains on the specific link between the mentioned factors and diabetes mellitus, with the Authority seeking to gather comprehensive insights and expert opinions to inform its investigation.

Key Provisions

The main operative sections of the Notice of Investigation under the Veterans' Entitlements Act 1986 (VEA) include sections 196G and 196B(7A) (section 196G). These sections outline the Repatriation Medical Authority's (the Authority) intention to conduct an investigation into immune-checkpoint inhibitors and interferon as factors contributing to diabetes mellitus, specifically in the context of Statements of Principles Instrument Nos. 48 and 49 of 2020 concerning diabetes mellitus (section 196G). The investigation will be initiated as per the provisions outlined in subsection 196B(7A) of the VEA (section 196B(7A)). The Authority is inviting written submissions from a range of stakeholders, including those eligible to make claims under the VEA or the Military Rehabilitation and Compensation Act 2004 (MRCA), organisations representing veterans and their dependants, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and individuals with relevant expertise (section 196G). The first meeting for this investigation is scheduled for 5 May 2021 (section 196G). The obligations imposed by this notice include the requirement for eligible persons and organisations to make written submissions to the Authority (section 196G). These submissions must be received by the Authority no later than 28 April 2021 (section 196G). The Authority provides several options for submitting these written submissions, including electronic lodgement via the RMA website, email, or postal mail (section 196G). The RMA website also offers guidelines for making submissions, and the RMA Secretariat is available for further assistance (section 196G). The notice explicitly states that all submissions must be in writing and include any relevant supporting information (section 196G). There are no explicit offences or penalties mentioned in the notice regarding the submission process or participation in the investigation (section 196G). However, failure to comply with the requirement to submit written submissions by the specified deadline may result in the Authority proceeding with the investigation without the input of those who did not submit timely and relevant information. The notice is clear that it invites participation and aims to gather comprehensive information from the specified groups to aid in the investigation's findings (section 196G).